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The Impact of Time to Thrombolytlc Therapy on 
Outcome In Patients With Acute Myocardial 
Infarction (AMi) 
P, Chareonthaitnwee, RJ, Gibbons, RS, Roberts, TrF Chnstian, R. Bums, 
S Yusut For the CORE Investigators; Ma]K~ Clinic, Rochester, Minnesota, 
USA; McMaMer Unit~erMy, Hami#on, O~tari~ Canada 
Pno~ ~t~m haNe suggested that the greatest t~f i t s  of e<lfly thromboly- 
sis may t~ o~zerv~ if administered within ~ holm of ~y~tom onset+ The 
Ipu~<~ of ~s  i~t ion  wi~ to exan~ne the impact of ~m to ~rom. 
bofy~ ~ on ~ AM! outcome velnaPles in CORE, ~n interr~ltional, 
~ e g  tn~! of pofoxamer 188, Mortal~ (M) 4nd remf4rctmn fate (RR) 
were meaI~red in 2,954 r ~  patients with AMI (.< 12 hogm' d~r~tmn) 
recewed ~ ther4~. S~m~cl~ umng T~em ~tam,t .  
lanai ~ (IS) and reldion~,mhde ~ electron ~ (EF) measured 
by ~mn~'al ~atones  mvOIved I,C~5 and 1,075 patmms, mspact~W, who 
amalyzable ~ .  ~ time to thrombalyttc therapy was ~gmfcantiy 
asso~ated ~ IS, EF, M. ned RR: 
Tume !o Theomtmlys+s 
IS |%LV) 19S t~ I~ 2"25:20  2411 19 2~S ~ 2~ 0.014 
EFt%) 051=.012 04S ¢014 048:013 048¢015 0008 
35~ M 1%) 55 70 77 t2a  00001 
E~t~tt  M |%) 69 S,2 10 1 155 <00001 
35-(t=-y RR t%l 62 32 4 I 09  0 0(~11 
Coe~t~s~ns: 1} There are c~emonstrabM benefits el eadre~ relped~smn 
therapy On m~a~ m..-e, election fradmn, and ~t ty .  2) +~baug~ rite effect of 
tin.re to ff~ron~d~'sis On in~,~'t stze and eiection fracton ~s pnmanly restricted 
to therapy ~ w~thm 2 hours e! sym~om onseL me effect of time on 
mo~alily is evident over all tm~e m~enrats. 3) Re~arctmn rate as htgl~r m 
patients Ireated ~ earker t h ~  t~erapy. 
Stenting: Carotid, Peripheral, Renal Diabetes 
(11), and Restenos is  I I  
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~ -~- -~ inRial With the Corvita Endoluminal  
Graft in Peripheral Arteries 
M Hemy, M Amo~. I. Henry. K. Tzvetanov. O. Tncodm. U CC.L. 
Potyctz.,~/ue. Essay-tee-Nancy. France 
Puq3Ose: To evaluate a self--expanding er~olummal vascular prostttes=s, the 
Con.ta Endoluminal Graft (CEG). allewm~ percutaneous bypass gm~ng m 
peni~erel artenes. 
Method and Matenats: The CEG census of 2 ~ n ~ :  a ~t-expand- 
ab~ cyfindncal wire ~ ,  a h~ghly porous, elast¢ coating on ,nner sur- 
face of structure, m wh~-'h b~ood can coagulate, seahng the CEG to form 
a new blood tight vessel wall. This flexible CEG can be compressed atria 
8.-10F introducer sheat'-s a,qo~ng porcutaneeus entry, ts produced an van- 
ous I~gths (3-30 cm). diameters (4 to 44 ram). cut to length by user, released 
from tn~r  sheath at intended site by coa.=al ~ of a "tlof~ng" 
catheter/slew pull back of the introducer sheath 
ResuffS: 58 pts (M: 46, F: 12. mean age: 644 ± 9.7 ym [39-86]) with 
occti.stve lesions (47)(sten.: 28, oocl.: 19), aneurysms (11), in lliac (35). 
temo~opop. (23) arteries treated with CEG. Mean lesion length: iliac~ 58.3 
± 24.3 mm (40-100), lemoropop.: 105.8 ± 7 ram. Mean % steno~s; 79 
± 6.2. 65 stents easily placed percutaneously (10 pts had contralateral 
approach). 6 lesions >12 cm treated ~th 2 overlapped slants. Immediate 
technical success: 100%. Complications: 7 thromboses titian: 2, femoropoD: 
5), 4 les~ons > 15 cm, requinng bypass (3), Fogarty (1). new angioptasty with 
success (3). At 6 months, 3 reslenoses appeared outside the ~iu.; trebled 
by now angioplast~,. Primary I~tency at 1 year: lliac: 95%, fern.pop.: 60% (p 
< 0.00t). Secondary patency respectively: 100, 75% (p < 0.001). 
Conclusion: The CEG seems an alternative to surgery to treat occlu- 
sive lesions and aneurysms, allowing true internal bypass by percutaneous 
approach. Yet, treatment of long lesions leads to higher thrombosis rate. 
~ Renal A 7 Year Single Center Arterial Stenting. 
Experience With a Serles of 206 Stented Artedes 
M Henry, M Amor, I. Henry, K. Tzvetanov, I. Masson, B. Mentre. 
Polyclinique, Essey-les-Nanc~. France 
Pu;pose: To evaluate the role of percutaneous tenting in the treatment of 
renal 9ffenal lestons 9fter failure of previous 10alloon angtoplasty. 
tv~thocl an<1M~tenats. 224 balloon e~panda¢~ steP~ (Palmaz: 164, AVE 
60) placed in 206 renal aNanea of 181 patHmt~ tectal ~ :  140, non. 
oatiol: 66) suffenng from HTN remtant to therapy (181), reflal dy~gnct~n 
(41) with 9theromatou~ (197), tibremu~ut4r (7), "rakay4shu (2) ¢J~ses. 
25 pts had t~laleral esions, 3 a solitary kidney, Ind~-.atmns'. uf~a~factory 
balloon ang~p~ resuits (173), mete.am (26), ~sse~n (7), Mean les~e 
length; 11,9 .+- 4.3 rnm (5-.30), M~n 4tlmo~e %: 623 ± 6.4 (70-100) 14 
very cal01i~ o~!  lemoni treate~ by Rofal01ator, 
~uIP~." gmmed~el~ leche~l success;205/?06,3 major ¢omplc~t~s 
(15%): 1 acu~_ mmm~is  cure¢l by fit~noly~, 1 aelanst perfom~on, 1 
artenal rapture (¢~th after surgery), 6 montt~ el~poo~ foaow.up m 
e l~ pts (175); rosteno~t# in I:~ pts (6.9%), Im~led by el new angmplaety. 
C!,~cal results: systolic blood pmssm drop from (mmH0) 1"/8 ± 9 to 141 
± 12 (p ~ 0,001) pant.slant, ~ ~ preuum (.wVHg) mop from 
106 ± 6 to B2 ± 10 (p .~ 0,01), ¢maumn (n~l) did nol ct~ange, nun~ of 
dmg~patmnt; baseline*. 2,6, pos1-~mt; 1,;2 (p < O,02-J, HTN; cured: 32/161 
(~) ,  iml~'Oved: 98/161 (61%), o~llanged: 30/161 (19%). Henal o~/sh~,~ 
tmn: Improved: 12/41 (30%), u~llanged; 27141 (1~%), ~ ;  ~41 (4%), 
At ? years, at! lesions: i~imary pstency: 76%, aecondary: ~%, non osl~t 
les~nS respectively 78, 100%, Ostlst leS~nS: BO elnd 93% (p:n.s.). 
Conc l~:  Renal aflery stsnting is sale, effe¢tNe, may be an alternative 
to Surgery. partlcutarty in o~tJal esK~ng. Our expenen~e shows md~ction m 
restenomS rote, compared to conventional angmptasty. All ostlal 
~l~ould be slanted. 
~ P ef~utaneous Endolumlnal Treatment of  
m l  Anoul~/ imL A Single Centl~ 
F ~  With e ~k~os of  3S Anouwsms 
M. Henry, M. Arose, I. Henry, K. Tzvetanov, P. Khofer. Po/yc//mque, 
~Na.c~,  France 
Purpose: To evalume fea~l~lfly, efficacy at percutaneous treatment of pe- 
npheral aneuq/sms t0,~th covered stents m most of the cases, Cragg Endopm 
System 1 (CES) and Corvita Endolummal Graft (CEG). 
Meft/o~ and Ma~J/a/s: 33 pts (M: 28, F: 5, mean age: 65.4 ± 9.6 yrs 
H7-83]) ~lh  35 aneurysms treated w~h covered stems (CES: 10, CEG: 13, 
non @ov~red stertts: 2, =i=~i graft: 1). ~ loCatlon: lenlorel ~'~.  
12. poplrteal: 8, d~c:15. Mean leslon length.61.1 mm± 21.3. Percutaneous 
approach used m all cases, femoral antegracle (n = 19), lemofal retrograde 
(n = 14), fern_ coqntralateral (n = 1). poptrteal (n = 1). Sten~ are ~tre~uced 
tt~ougll 7-10F st~eattts. Multiple slenl~ used to cov~r all les~ns in 8 cases 
Slants: from 6 to 12 mm in diameter, frem 30 to 120 mm in length. 
Re~.d~: Sten~ ~ implanled in 34 cases, no leakage. In 1 long, 
very tot'gJot~ femoropopliteal aneurysm, m'q3o~e to cover rts low pint. the 
dewce (CES) being too ng~d. No complication bserved unng the procedure. 
3 of 5 0evek~ non-+nfecllo~s fever/local pain with CES. 5 mremboses: 3 
in a palm,teal ane~ t in a femoral aneu~s,m treated by bypass, 1 In an 
thac aneu~am treated by Fogady techn=que. All othe~ slenis remaon patent, 
the aneuWSm completely exclucled o~er a mean follow-up of 13.3 ~ 10.4 
and a max. folfow.-up of 46 rrm:~m. Primary palency at 42 months: 
all Insane: T~=, ili~c ~teurysms: 100%, femoral aneurySm: 91%, poplttoat: 
34%. Secondary patertcy: all lemons: 85%, iliac aneurysms: 100%, femoral: 
91%. po~liteal- 56%. 
Cor~usnon: Percutaneous endelummal treatment of pen~ral  aneurysms 
seems safe. effect~e, effanng t~gh technical success with good told+term re- 
sults, except tot poptPeal ecalization. Long term result~ need to ba analyzed. 
Thts method could be an altematwe to surgical bypass and may be the first 
treatment o propose for this kind 01 disease. 
~ Percutaneous Endoluminal Treatment of 
Aorta-Abdominal  Occlusive Diseases 
M. Henry, M. Amor. I. Henry, K. Tzvetanov, B. Mentre, D. Weill. UCCI.. 
Pofycl/nKTue, Essey4es.Nancg France 
PurpOse: To evaluate the feasibility and efficacy of percutaneous endoluminal 
treatment of aorta-abdominal occlusive diseases. 
Methc~ and Materfafs: 28 pts (M: 25, P 3, mean age: 52.5 ± 11 3 ym) 
were treated by Percutaneous Transluminal Angtoplasty' (PTA) tar aorta- 
abdominal occluswe diseases. Lesions were located in the infremnal aorta 
alone (stenoses: 12). or extended 1o lilac artenes (stanoses: 12, occlusions: 
4). Mean % stenosiS: 80.4 ~_ 11.7. Mean lesion length: 33.5 ± 7.2 ram. 
7 lesions were calcified, 9 ulcerated. 16 excentrated. Owing to Fontatrm's 
clasmtication, 26 ~ were in stage It severe, 2 in stage III. 
Resu/ts: Technical success in al: cases (100%). The 4 oo:lusions were 
initially treated with tibnnolysis (3) or ultrasound mechanical thrombectomy 
device (1). Stentts were implanted in 23 pts (Palmaz in 18 pts, Wallstent 
in 2 and Optimecl in 3). A.B.I. increased from 0.63 :~ 0.15 to 0.97 ± 0.05. 
No immediate complication. Max. follow-up: 9 years, mean follow-up: 26.4 
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